Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Al-Kaisi F, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Eyre TA, Bygrave C, Kothari J, Basu S, Ramasamy K. Djebbari F, et al. Among authors: basu s. Br J Haematol. 2023 Apr;201(1):162-167. doi: 10.1111/bjh.18672. Epub 2023 Jan 31. Br J Haematol. 2023. PMID: 36720464 No abstract available.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
DPACE-based chemotherapy in the era of myeloma novel agents: A UK multicentre study.
Djebbari F, De Abrew K, Salhan B, Panitsas F, Hossain MI, Eyre TA, Willan J, Ramasamy K, Basu S, Jenner M, Kothari J. Djebbari F, et al. Among authors: basu s. Eur J Haematol. 2020 Aug;105(2):231-233. doi: 10.1111/ejh.13422. Epub 2020 Apr 21. Eur J Haematol. 2020. PMID: 32268442 No abstract available.
COVID-19 in haematology patients: a multicentre West Midlands clinical outcomes analysis on behalf of the West Midlands Research Consortium.
Morrissey H, Ball P, Mandal A, Nevil A, Paneesha S, Basu S, Karim F, Hossain MI, Phillips N, Khawaja J, Stone J, Murray D, Randall K, Murthy V, Kishore B, Nikolousis M, Pratt G, Neilson J, Pemberton N, Wandroo F. Morrissey H, et al. Among authors: basu s. Br J Haematol. 2021 Jan;192(1):e11-e14. doi: 10.1111/bjh.17136. Epub 2020 Nov 5. Br J Haematol. 2021. PMID: 33151540 Free article. No abstract available.
COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma.
Ramasamy K, Sadler R, Jeans S, Varghese S, Turner A, Larham J, Gray N, Barrett J, Bowcock S, Cook G, Kyriakou C, Smith D, Drayson M, Basu S, Moore S, McDonald S, Gooding S, Javaid MK. Ramasamy K, et al. Among authors: basu s. Br J Haematol. 2022 Jan;196(1):95-98. doi: 10.1111/bjh.17764. Epub 2021 Aug 2. Br J Haematol. 2022. PMID: 34341984 Free PMC article. No abstract available.
SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study.
Shields AM, Venkatachalam S, Shafeek S, Paneesha S, Ford M, Sheeran T, Kelly M, Qureshi I, Salhan B, Karim F, De Silva N, Stones J, Lee S, Khawaja J, Kaudlay PK, Whitmill R, Kakepoto GN, Parry HM, Moss P, Faustini SE, Richter AG, Drayson MT, Basu S. Shields AM, et al. Among authors: basu s. Clin Exp Immunol. 2022 Jan 28;207(1):3-10. doi: 10.1093/cei/uxab018. Clin Exp Immunol. 2022. PMID: 35020852 Free PMC article.
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response.
Ramasamy K, Sadler R, Jeans S, Weeden P, Varghese S, Turner A, Larham J, Gray N, Carty O, Barrett J, Bowcock S, Oppermann U, Cook G, Kyriakou C, Drayson M, Basu S, Moore S, McDonald S, Gooding S, Javaid MK. Ramasamy K, et al. Among authors: basu s. Br J Haematol. 2022 May;197(3):293-301. doi: 10.1111/bjh.18066. Epub 2022 Feb 17. Br J Haematol. 2022. PMID: 35064676 Free PMC article.
5,515 results